In summary, our data indicate that PRMT5 promotes CLL development, facilitates CLL progression to aggressive lymphoma through altered epigenetic programming, and provides a preclinical model and a therapeutic candidate to study CLL-to-RT progression. Here, PRMT5 is linked to lymphoma.